Compare VCEL & PDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VCEL | PDO |
|---|---|---|
| Founded | 1989 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 1996 | N/A |
| Metric | VCEL | PDO |
|---|---|---|
| Price | $32.55 | $13.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $58.50 | N/A |
| AVG Volume (30 Days) | 416.0K | ★ 777.7K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.80% |
| EPS Growth | ★ 60.00 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $276,259,000.00 | N/A |
| Revenue This Year | $19.09 | N/A |
| Revenue Next Year | $17.96 | N/A |
| P/E Ratio | $102.78 | ★ N/A |
| Revenue Growth | ★ 16.45 | N/A |
| 52 Week Low | $29.24 | $12.65 |
| 52 Week High | $48.75 | $14.25 |
| Indicator | VCEL | PDO |
|---|---|---|
| Relative Strength Index (RSI) | 32.64 | 28.74 |
| Support Level | $31.34 | $13.20 |
| Resistance Level | $38.48 | $13.61 |
| Average True Range (ATR) | 1.37 | 0.13 |
| MACD | -0.39 | -0.07 |
| Stochastic Oscillator | 3.03 | 17.70 |
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
PIMCO Dynamic Income Opportunities Fund is a closed-end management investment company. The fund's primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities.